102 related articles for article (PubMed ID: 9447960)
21. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Aug; 29(8):1990-1. PubMed ID: 16873829
[No Abstract] [Full Text] [Related]
22. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Bowker et Al.
Farooki A; Schneider SH
Diabetes Care; 2006 Aug; 29(8):1989-90. PubMed ID: 16873827
[No Abstract] [Full Text] [Related]
23. [Mode of action of hypoglycemic sulfanilamides].
Girardin E; Conte Devolx B
Therapie; 1991; 46(4):311-4. PubMed ID: 1948807
[TBL] [Abstract][Full Text] [Related]
24. The clinical use of oral sulfonylureas in the management of non-insulin dependent diabetes mellitus (NIDDM).
Ponte CD
W V Med J; 1990 Oct; 86(10):455-8. PubMed ID: 2238629
[TBL] [Abstract][Full Text] [Related]
25. [Sulfonylureas].
Sagreira L
Acta Med Port; 1989 Sep; Suppl 1():9S-13S. PubMed ID: 2694782
[TBL] [Abstract][Full Text] [Related]
26. [Hypoglycemic sulfamides: new pharmacologic data and practical implications].
Blickle JF; Brogard JM
Diabetes Metab; 1998 Jun; 24(3):276-80. PubMed ID: 9690064
[No Abstract] [Full Text] [Related]
27. [Incidence of severe secondary effects during treatment with sulfonylureas and biguanides].
Berger W
Journ Annu Diabetol Hotel Dieu; 1986; ():243-53. PubMed ID: 3613372
[No Abstract] [Full Text] [Related]
28. [Role of octreotide in the treatment of hypoglycemia induced by sulfonylureas].
Clerc D; Hugli O; Trueb L; Yersin B
Rev Med Suisse; 2008 Aug; 4(167):1764-7. PubMed ID: 18800755
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
Rosenkranz B
Horm Metab Res; 1996 Sep; 28(9):434-9. PubMed ID: 8911979
[TBL] [Abstract][Full Text] [Related]
30. Use of sulfonylurea agents in older diabetic patients.
Peters AL; Davidson MB
Clin Geriatr Med; 1990 Nov; 6(4):903-21. PubMed ID: 2224754
[TBL] [Abstract][Full Text] [Related]
31. [Diabetes mellitus and ischemic cardiopathy: potential effects of the use of sulfonylureas].
Gonçalves JV; Caldeira J
Rev Port Cardiol; 2001 Apr; 20(4):439-45. PubMed ID: 11433889
[TBL] [Abstract][Full Text] [Related]
32. Combination sulfonylurea-insulin therapy in the treatment of noninsulin-dependent diabetes mellitus.
Rosenblatt J
Conn Med; 1991 Nov; 55(11):634-6. PubMed ID: 1790695
[No Abstract] [Full Text] [Related]
33. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus.
Kabadi MU; Kabadi UM
Ann Pharmacother; 2003 Nov; 37(11):1572-6. PubMed ID: 14565810
[TBL] [Abstract][Full Text] [Related]
34. QT-interval dispersion in type 2 diabetic and non-diabetic patients with post-myocardial infarction.
Sakabe K; Fukuda N; Fukuda Y; Wakayama K; Nada T; Morishita S; Shinohara H; Tamura Y
Nutr Metab Cardiovasc Dis; 2008 Feb; 18(2):121-6. PubMed ID: 17346952
[TBL] [Abstract][Full Text] [Related]
35. Use of sulfonylureas during pregnancy: some incidental observations.
Zargar AH; Laway BA; Masoodi SR; Bashir MI; Bhat MH
J Assoc Physicians India; 2004 Feb; 52():168-9. PubMed ID: 15656061
[No Abstract] [Full Text] [Related]
36. Hypoglycaemia-induced myocardial infarction as a result of sulphonylurea misuse.
Corley BT; Davenport C; Delaney L; Hatunic M; Smith D
Diabet Med; 2011 Jul; 28(7):876-9. PubMed ID: 21204965
[TBL] [Abstract][Full Text] [Related]
37. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.
Simpson SH; Majumdar SR; Tsuyuki RT; Eurich DT; Johnson JA
CMAJ; 2006 Jan; 174(2):169-74. PubMed ID: 16415461
[TBL] [Abstract][Full Text] [Related]
38. Sulfonylureas. Why, which, and how?
Melander A; Lebovitz HE; Faber OK
Diabetes Care; 1990 Aug; 13 Suppl 3():18-25. PubMed ID: 2209339
[TBL] [Abstract][Full Text] [Related]
39. Does mortality risk vary among sulfonylureas?
Pantalone KM
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):6-7. PubMed ID: 25466240
[No Abstract] [Full Text] [Related]
40. Potential impact of sulfonylureas in the outcome of type 2 diabetic patients with ischemic stroke.
Arboix A
Stroke; 2007 Sep; 38(9):2413-4. PubMed ID: 17673799
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
